ArticleOxidative medicine and cellular longevity2020
Gut Bacteria Selectively Altered by Sennoside A Alleviate Type 2 Diabetes and Obesity Traits.
Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Changing Gastrointestinal Transit Time Alters Microbiome Composition and Bile Acid Metabolism: A Cross-Over Study in Healthy Volunteers.Neurogastroenterology and motility · 2025Trial
- Intermittent Fasting Amplifies Gut-Endocrine Axis Responses to Senna alexandrina Supplementation in Obese Rats.Molecular nutrition & food research · 2026Article
- Sennoside A Ameliorates Diabetic Atherosclerosis by Inhibiting OSCP1/ERK1/2 Pathway to Regulate Endothelial Dysfunction.Chinese journal of integrative medicine · 2026Article
- Role of gut microbiota in melanosis coli: from anthraquinone biotransformation to mucosal homeostasis dysbiosis.Frontiers in pharmacology · 2026Review
- Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.Frontiers in pharmacology · 2025Review
- Phage cocktail alleviated type 2 diabetes by reshaping gut microbiota and decreasing proinflammatory cytokines.Applied microbiology and biotechnology · 2024Article
- Medications that Regulate Gastrointestinal Transit Influence Inpatient Blood Glucose.medRxiv : the preprint server for health sciences · 2024Article
- Traditional Chinese medicine to improve immune imbalance of asthma: focus on the adjustment of gut microbiota.Frontiers in microbiology · 2024Review
- Targeted remodeling of the human gut microbiome using Juemingzi (Frontiers in cellular and infection microbiology · 2024Article
- The Effect of Chronic Laxative Use on Lipid Profile and HbA1c: A Hospital-Based Retrospective Study.Cureus · 2023Article
- Ferroptosis: a new strategy for Chinese herbal medicine treatment of diabetic nephropathy.Frontiers in endocrinology · 2023Review
- Role of anthraquinones in combating insulin resistance.Frontiers in pharmacology · 2023Review
- Exploration of the mechanisms underlying the beneficial effect of Luo Tong formula on retinal function in diabetic rats via the "gut microbiota-inflammation-retina" axis.Chinese medicine · 2022Article
- Article
- Sennoside A inhibits quorum sensing system to attenuate its regulated virulence and pathogenicityFrontiers in microbiology · 2022Article
- Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2021Review
- Alzheimer's Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models.Biomolecules · 2021Review
- Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound.Frontiers in pharmacology · 2021Review
- Rhubarb Supplementation Prevents Diet-Induced Obesity and Diabetes in Association with IncreasedNutrients · 2020Article
- Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives.Frontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidences implicate that gut microbiota play an important role in the onset and prolongation of fat inflammation and diabetes. Sennoside A, the main active ingredient of Rhizoma Rhei (rhubarb), is widely used for constipation as a kind of anthranoid laxative (e.g., senna). Here, we put forward the hypothesis that the structural alteration of gut microbiota in obesity mice may be involved in the pathogenesis of type 2 diabetes (T2D) which may be ameliorated by Sennoside A. We investigated the appearance of obesity, insulin resistance, host inflammation, and leaky gut phenotype with or without Sennoside A in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.